16.43%| YTD | 1Yr | 3Yr | 5Yr | 10Yr | |
| Fund | 16.43 | 20.06 | 0.39 | 7.66 | 11.75 |
| Classification | 14.59 | 17.02 | -1.33 | 3.01 | 6.37 |
| Index (S&P 500) | 20.90 | 21.30 | -6.10 | 0.30 | -0.70 |
| % Rank in Class (1-best,100=worst) | 39 | 36 | 25 | 8 | 13 |
| Investment Objective: | Health/Biotech |
|---|---|
| Net Assets ($Mil) | 258.00 |
| Inception Date: | 6/30/99 |
| Manager Name, Tenure | Team Managed, NA |
| Expense Ratio: | 1.19% |
|
Sales Charge:
Load Type:
|
Front-End Load 5.50% 0.00% |
| Company Name | Symbol | % Net Assets |
|---|---|---|
| Amag Pharmaceuticals Inc | AMAG | 5.32 |
| Vertex Pharma | VRTX | 4.31 |
| Alexion Pharm | ALXN | 4.05 |
| Allos Therapeutics Inc | ALTH | 3.95 |
| Celgene Corp | CELG | 3.77 |
| Gilead Sciences Inc | GILD | 3.53 |
| Utd Therapeut | UTHR | 3.48 |
| Shire | SHPGY | 3.45 |
| Biomarin Pharmaceutical Inc | BMRN | 3.34 |
| Amgen | AMGN | 2.85 |
| % of Total Holdings | 38.05 | |